Schneyer Mark C. 4

What Happened
Mark C. Schneyer, Chief Financial Officer of ACADIA Pharmaceuticals (ACAD), reported RSU activity and an open-market sale. On April 5, 2026, 5,276 restricted stock units converted into 5,276 shares. A portion/all of those shares were used to satisfy tax withholding (reported as a derivative disposition). On April 7, 2026, Schneyer sold 2,709 shares in the open market at $22.20 per share, generating $60,140. These transactions reflect vesting and tax-related selling rather than a new purchase.

Key Details

• Transaction dates & prices:
  • 2026-04-05: Conversion/settlement of 5,276 RSUs into 5,276 shares (derivative conversion).
  • 2026-04-05: Disposal of 5,276 shares reported at $0 — used to cover tax withholding (per footnote).
  • 2026-04-07: Open-market sale of 2,709 shares at $22.20 each for $60,140.
• Shares owned after transaction: Not specified in this Form 4 filing.
• Footnotes of note:
  • F1: Each restricted stock unit (RSU) equals a contingent right to one share.
  • F2: Mandatory sales were made to cover withholding taxes and are intended to comply with Rule 10b5-1(c) requirements.
  • F3: RSUs vest in four equal annual installments beginning April 5, 2023.
• Filing: Form 4 filed April 7, 2026 (timely reporting for transactions occurring April 5, 2026).
• Insider status: Executive (CFO); not reported as a 10% owner.

Context
This activity reflects routine RSU vesting and tax-withholding mechanics: RSUs converted to shares and some shares were withheld/sold to satisfy taxes, with an additional open-market sale reported. Such tax-related sales are common and do not necessarily indicate a change in the insider’s view of the company.